U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for Treatment of Adults and Adolescents with Hemophilia A or B
On Oct. 11, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved HYMPAVZIâ„¢ (marstacimab-hncq)…